Tidal Investments Adds $35M in AstraZeneca PLC ($AZN)
The fund boosted its stake in AstraZeneca by over 878% in the latest quarter.
Key Points
- Tidal Investments increased its AstraZeneca stake by 878.77%, adding 194,586 shares to total 216,729 shares valued at $38.74 million.
- AstraZeneca's stock trades near $178.75 with a market cap of $277.22 billion and a P/E ratio of 26.96.
- Insider Mani Sharma sold 11,893 shares on May 20, 2026, while analysts maintain a strong buy consensus with a mean target price of $224.49.
Tidal Investments has significantly increased its stake in AstraZeneca PLC (NYSE:AZN). The latest 13F filing reveals that the fund boosted its holdings by 878.77%, adding 194,586 shares. The fund now holds 216,729 shares valued at approximately $38.74 million as of the reporting period ending March 31, 2026.
What Changed in Tidal Investments' AstraZeneca Position
Tidal Investments previously held 22,143 shares of AstraZeneca. By the end of the quarter, this had surged to 216,729 shares, marking an increase of 194,586 shares. This substantial move reflects a strong interest in AstraZeneca, with the value of the holdings at about $38.74 million.
Other Institutional Activity in AstraZeneca
Several other institutional investors also adjusted their positions in AstraZeneca. Investor AB added 51,587,810 shares, bringing its total to 51,587,810 shares worth approximately $10.17 billion. Vanguard Capital Management LLC increased its holdings by 45,040,142 shares, ending with 45,040,142 shares valued at about $8.81 billion. Capital International Investors grew its position by 19,871,935 shares to a total of 34,393,013 shares, valued at around $6.72 billion. FMR LLC added 7,752,869 shares, reaching a total of 29,601,724 shares worth about $5.80 billion. Meanwhile, Capital World Investors significantly increased its stake by 27,350,501 shares to 28,264,580 shares, valued at $5.52 billion.
AstraZeneca Stock Snapshot
Shares of AstraZeneca PLC (NYSE:AZN) are currently trading near $178.75. The company has a market capitalization of $277.22 billion and a P/E ratio of 26.96. Its forward P/E is 22.23, with a beta of 0.214, indicating lower volatility compared to the market. AstraZeneca's 52-week range is between $137.22 and $212.71. The stock's 50-day moving average is $189.14, while the 200-day moving average is $182.05. The company maintains a current ratio of 0.909 and a quick ratio of 0.701, with a debt-to-equity ratio of 71.815.
Recent Earnings
In its recent earnings report, AstraZeneca posted revenue of $60.44 billion, reflecting a growth of 12.5%. The company's net margin stands at 17.19%, and it achieved a return on equity of 23.48%. Earnings per share (EPS) were reported at $6.63. AstraZeneca is expected to announce its next earnings on July 27, 2026.
Dividend
AstraZeneca pays an annual dividend rate of $3.16, which translates to a yield of 1.77%. The dividend payout ratio is 47.7%, indicating a moderate portion of earnings being returned to shareholders.
Insider Buying and Selling at AstraZeneca PLC
Recent insider activity includes the sale of 11,893 shares by Mani Sharma, Senior Vice President and Group Controller, on May 20, 2026, at an average price of $185.78. Earlier, Sharma purchased 1 share on May 6, 2026, at $186.28, and another on April 7, 2026, at $196.03. Notably, Aradhana Sarin sold 15,000 shares on November 12, 2025, at $88.88.
Analysts Set New Price Targets
Analysts remain optimistic about AstraZeneca, with several firms maintaining strong buy ratings. The consensus is a strong buy, with a mean target price of $224.49 based on 10 analyst opinions. On August 12, 2024, Cowen & Co. maintained its buy rating with a $95 target. Similarly, on July 26, 2024, Leerink Partners reiterated its buy rating with a $136 target.
About AstraZeneca
AstraZeneca PLC is a leading biopharmaceutical company headquartered in Cambridge, United Kingdom. It focuses on the discovery, development, and commercialization of prescription medicines in areas like oncology, cardiovascular, renal, and respiratory diseases. Led by CEO Pascal Soriot, AstraZeneca employs around 96,100 people and operates globally, serving a wide range of healthcare needs.
Bottom Line
The significant increase in AstraZeneca holdings by Tidal Investments highlights growing institutional interest in the company. Investors often track such moves for insights, but it's important to remember that 13F filings are backward-looking and may not reflect current positions. AstraZeneca's robust market position and analyst confidence suggest continued interest in its stock.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.